1-6 of 6
Salvo Mirto, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Roberto Crocchiolo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Mario Boccadoro, MD, Fabio Ciceri, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD
Journal: Blood
Blood (2007) 110 (11): 1889.
https://doi.org/10.1182/blood.V110.11.1889.1889
Published: 2007
Journal Articles

A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).

Sergio Cortelazzo, MD, Atto Billio, MD, Alessandro Rambaldi, MD, Corrado Tarella, MD, Ingnazio Majolino, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD, Catterina Patti, MD, Salvo Mirto, MD, Giovanna Borrelli, PhD, Roberto Marchioli9, MD
Journal: Blood
Blood (2007) 110 (11): 1898.
https://doi.org/10.1182/blood.V110.11.1898.1898
Published: 2007
Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.

Manuela Zanni, MD, Michele Magni, MD, Alessandro Rambaldi, MD, Fabio Benedetti, MD, Roberto Passera, PhD, Caterina Patti, MD, Guido Parvis, MD, Fabio Ciceri, MD, Andrea Gallamini, MD, Sergio Cortelazzo, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Paolo Corradini, MD, Mario Boccadoro, MD, Giuseppe Saglio, MD, Giovanni Pizzolo, MD, Tiziano Barbui, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2007) 110 (11): 1083.
https://doi.org/10.1182/blood.V110.11.1083.1083
Published: 2007
Journal Articles

Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma

Sergio Cortelazzo, MD, Michele Magni, MD, Corrado Tarella, MD, Michael Mian, MD, Atto Billio, MD, Andrea Rossi, MD, Maddalena Marchesi, MD, Andrea Gallamini, MD, Paolo Corradini, MD, Fabio Ciceri, MD, Guido Parvis, MD, Ignazio Majolino, MD, Caterina Patti, MD, Salvo Mirto, MD, Fabio Benedetti, MD, Giovanni Pizzolo, MD, Alessandro M. Gianni, MD, Alessandro Rambaldi, MD
Journal: Blood
Blood (2007) 110 (11): 1282.
https://doi.org/10.1182/blood.V110.11.1282.1282
Published: 2007
Journal Articles

High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ).

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Alessandra Pescarollo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Michele Magni, MD, Liliana Devizzi, MD, Mario Boccadoro, MD, Marco Bregni, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD
Journal: Blood
Blood (2005) 106 (11): 2068.
https://doi.org/10.1182/blood.V106.11.2068.2068
Published: 2005
Journal Articles

Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.

Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Alessandra Pescarollo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Liliana Devizzi, MD, Mario Boccadoro, MD, Ignazio Majolino, MD, Marco Bregni, MD, Andrea Gallamini, MD, Salvo Mirto, MD, Marco Ladetto, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2004) 104 (11): 891.
https://doi.org/10.1182/blood.V104.11.891.891
Published: 2004